Wockhardt receives final approval from USFDA for Olopatadine HCI

04 Jul 2017 Evaluate

Wockhardt has received final approval from United States Food and Drug Administration (USFDA) for its ANDA for 0.1% ophthalmic solution of Olopatadine HCI. The eye drop Olopatadine HCI 0.1% ophthalmic solution is a generic version of Patanol, marketed at US by Alcon, a subsidiary of Novartis.

The product will be manufactured at USFDA approved contract manufacturing organization based in Montreal, Canada.

Wockhardt is one of the few companies with end to end integrated capabilities for its products, starting with the manufacture of the oral and sterile API’s, the dose forms and marketing through wholly owned subsidiary in the US, enabling the company to capture maximum value.


Wockhardt Share Price

1345.90 -17.25 (-1.27%)
23-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1631.65
Dr. Reddys Lab 1235.15
Cipla 1314.85
Zydus Lifesciences 881.95
Lupin 2137.15
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×